A study testing whether a GLP-1 medicine from Children's Hospital Los Angeles, semaglutide, can help with weight.
What this means for you
- Who can join
- Children and teens 12 to 18, have obesity, BMI 35+.
- What you take
- semaglutide, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.
- How long it lasts
- The full study runs about 7.4 years; your own time in it is usually shorter.
- What you get
- The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.
What this study is for
Primary condition: Pediatric Obesity. Also studied in: Metabolic and Bariatric Surgery, Semaglutide.
Full scientific study title: Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth.
Who can join
Children and teens 12 to 18, have obesity, BMI 35+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- ages 12 to 18 years
- Tanner stage 3 or higher
- severe obesity (defined as a BMI greater than 35 kg/m2 or BMI >=140% of the 95th percentile)
- currently undergoing primary surgical weight loss through the pediatric bariatric surgery pathway at Children's Hospital Los Angeles
- be willing to have blood collected before and after surgical procedure at defined points
Key exclusion criteria
- have a previous diagnosis of type 1 diabetes
- taking any medications known to influence body composition or prevent weight loss or promote weight gain (e.g. prednisone)
- have been diagnosed with syndromes or diseases that may influence the postoperative course (e.g., Cushing syndrome, Down syndrome, Prader Willi Syndrome)
- have significant comorbid medical conditions necessitating frequent hospitalization that may require interruption of medications and/or that would make early re-initiation of semaglutide unsafe due to the other medical comorbidities
- refuse to comply with eligibility criteria.
Where this study is enrolling
This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.
California1 site
- Children's Hospital Los AngelesLos Angeles, California
Timeline
Started enrolling: 2026-06-01. Expected completion: 2033-11-01. Last updated on ClinicalTrials.gov: 2026-03-17.
Official source
We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
